After chemotherapy for testicular germ-cell cancer, a CT scan may show that a lump or enlarged lymph node remains in the retroperitoneum—the area at the back of the abdomen near the aorta, inferior vena cava, kidneys and ureters. This is often described in reports as a “residual retroperitoneal mass”, “residual para-aortic mass”, “persistent retroperitoneal lymphadenopathy” or “residual nodal disease”.
A residual mass does not automatically mean that active cancer is still growing. Depending on the tumour type and treatment response, it may contain mature teratoma, viable germ-cell cancer, scar tissue or necrosis. CT imaging alone cannot always distinguish these possibilities. The next step depends on the original histology, post-chemotherapy tumour markers, size and location of the residual mass, change on serial scans, and the treatment already received.
Tumour markers can be normal even when a residual mass contains teratoma. Normal AFP and beta-hCG are reassuring in context, but they do not prove that a residual mass is harmless.
No. The decision depends strongly on whether the original cancer was non-seminoma or pure seminoma, the size and location of the residual mass, tumour-marker results and the response to treatment.
For non-seminomatous germ-cell tumours, post-chemotherapy RPLND is commonly considered when a residual retroperitoneal mass remains and tumour markers have normalised or are appropriately declining, provided the patient is fit for surgery. The aim is to remove residual disease that may contain teratoma or viable tumour and to obtain a definitive histopathological diagnosis.
In many guideline-based pathways, a residual retroperitoneal mass larger than 1 cm in greatest transverse diameter after first-line chemotherapy for NSGCT is evaluated for surgical removal. The exact decision must be made by the treating specialist, taking account of imaging, marker trends, the original tumour and clinical circumstances. Smaller residual lesions may be managed differently and need individual review.
Pure seminoma is managed differently. A residual mass may consist of fibrosis or necrosis, and surgery is not routinely performed for every residual seminoma mass. For a residual mass larger than 3 cm, FDG-PET/CT may be considered at an appropriate interval after chemotherapy, commonly at least 6 weeks, to help assess for viable disease. A positive PET result is not definitive by itself and may need reassessment, repeat imaging, biopsy or specialist discussion. Decisions should follow current guideline recommendations and multidisciplinary review.
If the diagnosis is mixed germ-cell tumour or the original histology is uncertain, management should be individualised based on expert pathology review and the complete clinical picture.
Post-chemotherapy RPLND (retroperitoneal lymph node dissection) is an operation to remove residual lymph-node tissue or a mass from the back of the abdomen after chemotherapy for testicular cancer. The mass may be close to major vessels such as the aorta and inferior vena cava, the renal vessels, ureters and bowel. This can make surgery technically demanding, particularly when chemotherapy has caused inflammation and fibrosis around the tumour.
The objective is complete removal of the indicated residual disease while protecting major blood vessels and nearby organs. The required extent of surgery depends on the distribution of the mass, the original tumour, previous treatment and specialist assessment. Some cases require removal of adjacent structures if they are involved or inseparable from the mass.
Post-chemotherapy residual masses can be adherent to or wrap around major blood vessels and may lie near the renal vessels, ureters and bowel. Pre-operative planning should include detailed review of the actual CT images, tumour-marker trends, the original histopathology and chemotherapy records. In selected cases, a multidisciplinary team may include urologic oncology, medical oncology, radiology, pathology, vascular surgery and anaesthesia.
The approach—open, laparoscopic or robotic—is chosen according to the size, location and complexity of the mass, previous treatment, the need for complete removal and the experience of the treating team. Large or vessel-involving post-chemotherapy masses often require an open approach, but the decision is case-specific. A minimally invasive approach should not compromise completeness or safety.
The surgeon exposes the retroperitoneum, identifies important anatomical structures and removes the residual mass with the required lymph-node tissue. The operation may involve dissection around or reconstruction of major vessels in selected cases. The mass and lymph-node tissue are sent for detailed histopathological examination.
The final report may show mature teratoma, viable germ-cell tumour, necrosis/fibrosis or a combination. These findings help determine whether surveillance or further treatment is needed. The pathology result should be interpreted alongside tumour markers and the complete treatment history.
Post-chemotherapy RPLND can be more complex than primary RPLND. Potential risks include:
The risk varies considerably with mass size, vessel involvement, chemotherapy-related fibrosis, prior operations and the patient’s overall condition. Your surgeon should explain the risks that are most relevant to your scan and treatment history.
Discuss fertility before treatment whenever possible. Sperm banking may be appropriate if future biological parenthood is important to you. Post-chemotherapy RPLND can affect ejaculation, particularly if the relevant nerve pathways are involved or cannot be preserved safely. Nerve-sparing may be possible in selected cases but cannot be guaranteed.
Erection, sexual desire and ejaculation are separate functions. Ask the treating team how the planned operation may affect each one, what fertility options may remain, and whether additional support is needed after treatment.
Recovery depends on the extent of surgery, whether vascular or adjacent-organ procedures are needed, prior chemotherapy and any complications. The team will guide mobilisation, pain relief, diet progression, wound care and return to daily activities. Follow the surgeon’s instructions about lifting, driving, work and exercise.
The pathology result is important, but it is only one part of follow-up. Ongoing review may include symptoms, examination, AFP/beta-hCG/LDH and imaging according to the histology, stage and treatment received. Keep scheduled follow-up even if tumour markers are normal and you feel well.
Not necessarily. It may be teratoma, viable cancer or scar/necrotic tissue. The meaning depends on histology, markers, imaging and response to treatment.
Yes. Mature teratoma may remain even when AFP and beta-hCG are normal. Normal markers do not rule out teratoma in a residual mass.
No. Management differs between non-seminoma and seminoma and depends on mass size, markers, timing of imaging and the full clinical picture.
Chemotherapy can cause fibrosis and adhesions around the mass, which may be close to major blood vessels, renal vessels, ureters and bowel.
A minimally invasive approach may be possible in selected cases, but many bulky or complex masses need open surgery. The approach must prioritise complete removal and safety.
This may mean no viable tumour or teratoma was found in the removed specimen. The follow-up plan still depends on the full pathology, stage and treatment history.
Not everyone does. Further treatment depends on the final pathology, tumour markers, prior chemotherapy and specialist recommendations.
Bring the original histopathology, orchidectomy notes, chemotherapy summary, serial tumour-marker reports and the actual CT images before and after chemotherapy.
| Histology | What it means | Usual next step |
|---|---|---|
| Necrosis or fibrosis | Scar tissue with no viable tumour | Follow-up after resection |
| Mature teratoma | Chemo-resistant, can grow or transform | Complete surgical removal |
| Viable germ-cell cancer | Active tumour left after chemotherapy | Removal, often followed by further systemic treatment |
Not necessarily. A residual mass may be necrosis or fibrosis, mature teratoma, or viable germ-cell cancer. Imaging cannot reliably tell these apart, so pathology after resection gives the definitive answer.
For non-seminomatous germ-cell tumours, resection is generally considered when a residual retroperitoneal mass larger than 1 cm remains after chemotherapy and AFP and beta-hCG have normalised. Residual masses in seminoma are usually observed or assessed with PET-CT first.
Mature teratoma does not respond to chemotherapy, can keep growing and may undergo malignant transformation, so complete surgical removal is advised when it is feasible.
Selected videos and anonymised case summaries from Dr Swati Shah’s testicular cancer practice, shared for patient education. Every patient’s plan is individual, and a past case does not predict an individual result.
Advanced testicular cancer can still be curable, even when large residual lymph node masses remain after chemotherapy.
In this case, a 30-year-old man with a mixed germ cell tumor of the testis received systemic chemotherapy and subsequently underwent evaluation for a residual retroperitoneal lymph node mass. PET-CT showed significant residual masses measuring approximately 6 × 5 cm and 5 × 5 cm, located close to major blood vessels, including the aorta, inferior vena cava (IVC), and renal vessels.
Because of the size and location of the residual disease, surgery was technically challenging. The patient underwent exploratory laparotomy with retroperitoneal lymph node dissection (RPLND). Despite the close relationship of the tumor to the major vessels, a complete surgical resection was achieved safely, with removal of all visible residual tumor tissue.
When a testicular tumour is suspected, the surgical approach is extremely important. A scrotal incision should generally be avoided because it can disrupt the normal lymphatic drainage pathways of the testis and potentially increase the risk of local tumour contamination and altered patterns of spread.
The standard oncological procedure for a suspected testicular malignancy is high inguinal orchidectomy. Through an inguinal approach, the testis is delivered and removed along with the spermatic cord and its vascular and lymphatic pedicle, providing appropriate oncological control and allowing accurate histopathological diagnosis.
This is an important surgical principle: the first incision matters. An incorrect approach can complicate subsequent management, while the appropriate initial procedure can help ensure proper staging and treatment.
जब टेस्टिकुलर ट्यूमर (Testicular Tumour) का संदेह हो, तो सर्जरी का सही तरीका बहुत महत्वपूर्ण होता है। आमतौर पर अंडकोष (Scrotum) पर चीरा लगाने से बचना चाहिए, क्योंकि इससे अंडकोष की सामान्य लिम्फेटिक ड्रेनेज (Lymphatic drainage) प्रभावित हो सकती है और स्थानीय रूप से ट्यूमर कोशिकाओं के फैलने तथा बीमारी के फैलाव के तरीके में बदलाव का जोखिम बढ़ सकता है।
संदिग्ध टेस्टिकुलर कैंसर में मानक ऑन्कोलॉजिकल सर्जरी हाई इंग्वाइनल ऑर्किडेक्टॉमी (High Inguinal Orchidectomy) है। इसमें जांघ के ऊपरी हिस्से के पास इंग्वाइनल (Inguinal) रास्ते से अंडकोष को बाहर निकालकर, उसे स्पर्मेटिक कॉर्ड (Spermatic cord) तथा उसकी रक्त वाहिकाओं और लिम्फेटिक पेडिकल (Lymphatic pedicle) सहित हटाया जाता है। इससे उचित कैंसर सर्जरी सुनिश्चित होती है और सही हिस्टोपैथोलॉजिकल डायग्नोसिस (Histopathological diagnosis) में मदद मिलती है।
यह एक महत्वपूर्ण सर्जिकल सिद्धांत है: पहला चीरा बहुत मायने रखता है। गलत तरीके से किया गया पहला ऑपरेशन आगे के उपचार को जटिल बना सकता है, जबकि सही शुरुआती सर्जिकल प्रक्रिया बीमारी की उचित स्टेजिंग और आगे के उपचार में मदद करती है।
This video presents a compelling testimonial from a testicular cancer survivor who received life-saving treatment from Dr. Swati Shah, an expert Uro and Gynecological Oncologist. In the brief clip, the patient recounts their challenging medical journey, focusing on the critical decision-making process regarding their surgical treatment plan. Initially confronted with the difficult prospect of traditional open surgery—which typically involves a longer, more painful healing process—the patient instead opted for a state-of-the-art robotic surgery performed by Dr. Shah. The survivor shares how this advanced, minimally invasive approach made a massive difference in their overall recovery.
In the video, He speaks in Gujarati, sharing his personal experience. He explains that he initially visited the clinic because he was experiencing significant pain. After a thorough medical evaluation, he was diagnosed with cancer and advised to undergo surgical intervention. Guided by the medical expertise of Dr. Swati Shah, He confidently went ahead with the recommended operation. The surgery was a success, and he reports receiving a highly positive response to the procedure. Following the operation, his comprehensive treatment plan also included a round of chemotherapy to reduce the risk of relapse.
The patient explains that he was initially diagnosed with testicular cancer five years ago. Unfortunately, eight months prior to the video, he faced a recurrence involving a retroperitoneal lymph node. After finding Dr. Swati Shah online, he underwent a complex robotic Retroperitoneal Lymph Node Dissection (RPLND) surgery performed by her. Speaking just two months post-operation, the patient highlights his remarkably smooth and rapid recovery, noting that his follow-up medical reports have all been positive. He expresses deep gratitude and recommends Dr. Shah.
A 30-year-old man with metastatic germ cell tumour had a 4.5 cm calcified retroperitoneal mass and persistent pelvic lymphadenopathy after chemotherapy. The mass lay close to major vessels, so complete clearance by robotic RPLND was planned.
A 27-year-old man had residual retroperitoneal nodal masses after several cycles of chemotherapy for recurrent NSGCT of the right testis. A 3 × 3 cm solid-cystic mass adherent to the aorta raised concern for chemo-resistant mature teratoma, and surgery was advised.
Details are anonymised and shown for education only.
Dr. Swati Shah operated successfully and provided excellent care throughout the treatment. She is highly skilled, compassionate, and undoubtedly the best doctor for testis cancer in Ahmedabad. We are very thankful for her guidance and expertise
I had an excellent experience with Dr. Swati Shah. She is one of the most skilled and compassionate doctors I have ever met. Her approach is very professional, and she explains every step of the treatment with great patience and clarity. The surgery was successful, and recovery was smooth under her guidance.
We had surgery done in Apollo Hospital. The doctor is very good and has done the options in a very good way. Now everything is fine.
Dr. Swati H. Shah is a uro- and gynaecologic oncosurgeon in Ahmedabad with experience in cancer surgery, robotic surgery and complex retroperitoneal tumour surgery. Her work includes testicular cancer surgery and the management of selected retroperitoneal masses. Decisions about post-chemotherapy surgery are individualised after review of pathology, tumour markers, imaging and previous treatment.
If a CT scan after chemotherapy reports a “residual retroperitoneal mass”, “residual para-aortic mass”, “persistent retroperitoneal lymphadenopathy” or “residual nodal mass”, a specialist review can help clarify whether surveillance, additional assessment or surgery is appropriate.
Bring the original testicular histopathology, orchidectomy operative note, chemotherapy records, serial AFP/beta-hCG/LDH results and the actual CT images from before and after treatment.
Shah’s Cancer & Robotic Surgery Centre, Gota, Ahmedabad | Apollo Hospital International, Ahmedabad
Appointment contact: +91 63590 11009
This page is for general education and does not replace an individual medical consultation.
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.
